Prevention of breast cancer in women with a BRCA1 germline mutation
Conditions
Brief summary
Time to the occurrence of any breast cancer (invasive or DCIS)
Detailed description
Time to invasive breast cancer, Time to invasive triple negative breast cancer, Time to ovarian, fallopian tube or primary peritoneal cancer (in women who have not undergone PBSO), Time to other (non breast or ovarian cancer) malignancies, including those known to be associated with BRCA1 mutations, Time to clinical fractures in pre- and postmenopausal women, Frequency of breast biopsies and frequency of benign breast lesions
Interventions
DRUGIdentical to the Test product
Sponsors
Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group, Institut Catala D'oncologia, ANZ Breast Cancer Trials Group Limited, University Of Manchester, Alliance Foundation Trials LLC, Shaare Zedek Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to the occurrence of any breast cancer (invasive or DCIS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to invasive breast cancer, Time to invasive triple negative breast cancer, Time to ovarian, fallopian tube or primary peritoneal cancer (in women who have not undergone PBSO), Time to other (non breast or ovarian cancer) malignancies, including those known to be associated with BRCA1 mutations, Time to clinical fractures in pre- and postmenopausal women, Frequency of breast biopsies and frequency of benign breast lesions | — |
Countries
Austria, Germany, Spain
Outcome results
None listed